Drug intelligence / Profile preview

MyBONE

Development stage: Unknown
Lead developer: Docventures
Modality: Small Molecules
Administration: Oral

Overview

MyBONE is an oral nutritional supplement developed and marketed by Docventures Pharmaceuticals Pvt Ltd. It is a fixed-dose combination product containing calcium carbonate (500 mg) and vitamin D3 (cholecalciferol, 250 IU). The supplement is indicated for the treatment and prevention of calcium and vitamin D deficiencies, and is prescribed for the management of bone-related conditions such as osteoporosis, rickets, osteomalacia, and hypoparathyroidism. Calcium carbonate provides elemental calcium essential for bone mineralization and structural integrity, while vitamin D3 acts as an agonist at the vitamin D receptor (VDR) to enhance intestinal calcium absorption and maintain phosphate homeostasis.

Brand names: MyBONE

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on MyBONE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MyBONE.

Explore the full profile